Navigation Links
NW Bio Presenting At Phacilitate Immunotherapy World Conference
Date:1/19/2017

BETHESDA, Md., Jan. 18, 2017 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, announced today that Dr. Marnix Bosch, Chief Technical Officer of NW Bio, will present at the Phacilitate Immunotherapy World Conference on Thursday, January 19, 2017, at the Hyatt Regency Hotel in Miami, Florida.

Dr. Bosch will chair the session entitled "New Therapeutic Approaches – Expanding the Reach of Cancer Immunotherapy to All Patients In Need of Better Treatments,"  taking place from 4:30 p.m. to 5:35 p.m. on Thursday, January 19, and will make a presentation on the same subject.  There will not be a webcast. The presentation was originally scheduled to be made by Ms. Linda Powers, CEO of NW Bio, but she was unable to do so due to illness.

The annual Phacilitate Immunotherapy World Forum is one of the world's largest and fastest growing senior-level immuno-oncology business meetings, with the global immuno-oncology community's premier thought-leaders and decision-makers. 

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe.  The Company has a broad platform technology for DCVax dendritic cell-based vaccines.  The Company's lead program is a 348-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM), which is on a partial clinical hold in regard to new screening of patients.  GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease."  The Company is under way with a 60-patient Phase I/II trial with DCVax-Direct for all inoperable solid tumors cancers, with a primary efficacy endpoint of tumor regression.  It has completed enrollment in the Phase I portion of the trial.  The Company previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer.  The Company conducted a Phase I/II trial with DCVax for metastatic ovarian cancer together with the University of Pennsylvania.  In Germany, the Company has received approval of a 5-year Hospital Exemption for the treatment of all gliomas (brain cancer) patients outside the clinical trial.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expect," "believe," "intend," "design," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the Company's ongoing ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, uncertainties about the clinical trials process, uncertainties about the timely performance of third parties, risks related to whether the Company's products will demonstrate safety and efficacy, risks related to the Company's and Cognate's abilities to carry out the intended manufacturing expansions contemplated in the Cognate Agreements, risks related to the Company's ability to carry out the Hospital Exemption program and risks related to possible reimbursement and pricing.  Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings.  Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nw-bio-presenting-at-phacilitate-immunotherapy-world-conference-300393026.html


'/>"/>
SOURCE Northwest Biotherapeutics
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. RepliCel Presenting at InvestMNT Investor Conference in Minneapolis
2. The Remedy Group presenting at the 2015 Armada Specialty Pharmacy Summit: The Pitfalls to Growth and Maintaining the Patient Experience
3. Don't miss the I2SL High-Tech Talks Webinar Series Presenting: Butler University's Renovation With Filtered Fume Hoods, 3 Years Later
4. Presenting Agile and Scrum Private Trainings in Kansas by Conscires Agile Practices
5. Dr. Szczepan Baran will be Presenting at the International Microsurgical Simulation Society at Columbia University in New York
6. GenVec to Present at Phacilitate Cell & Gene Therapy World 2017
7. Caris Life Sciences and the Lustgarten Foundation Collaborate to Support Immunotherapy Clinical Trial for Pancreatic Cancer
8. SITC Seeking Applicants for Fellowships Supporting Cancer Immunotherapy Researchers
9. First Immunotherapy Treatment Guidelines Published for Hematologic and Prostate Cancers
10. Tempus Announces Collaboration with Abramson Cancer Center at Penn to Increase the Effectiveness of Immunotherapy Treatment
11. First Kidney Cancer Treatment Guideline Published Focused on Immunotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... A ... pregnancy rates in frozen and fresh in vitro fertilization (IVF) transfer ... age to IVF success. , After comparing the results from the fresh and ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building ... corporate rebranding initiative announced today. The bold new look is part of a ... company moves into a significant growth period. , It will also expand its service ...
(Date:10/10/2017)... , ... October 10, 2017 , ... ... Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives of the ... for Excellence in Volunteer Experience from US2020. , US2020’s mission is to change ...
(Date:10/10/2017)... research firm Parks Associates announced today that Tom Kerber ... Annual Meeting , October 11 in Scottsdale, Arizona . ... how smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the ...
Breaking Biology Technology:
(Date:10/4/2017)... Oct. 4, 2017  GCE Solutions, a global clinical research organization ... document anonymization solution on October 4, 2017. Shadow is designed to ... comply with policy 0070 of the European Medicines Agency (EMA) in ... ... ...
(Date:6/23/2017)... N.Y. and ITHACA, N.Y. ... ) and Cornell University, a leader in dairy research, ... with bioinformatics designed to help reduce the chances that ... With the onset of this dairy project, Cornell University ... Consortium for Sequencing the Food Supply Chain, a food ...
(Date:5/6/2017)... , May 5, 2017 RAM ... announced a new breakthrough in biometric authentication based ... quantum mechanical properties to perform biometric authentication. These new ... semiconductor material created by Ram Group and its ... entertainment, transportation, supply chains and security. Ram Group ...
Breaking Biology News(10 mins):